Literature DB >> 9284280

Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria.

J Weglage1, K Ullrich, M Pietsch, B Fünders, F Güttler, E Harms.   

Abstract

Based on the serum phenylalanine levels under free diet patients with hyperphenylalaninemia are classified as "classical" (>1200 micromol/L), "mild" (600-1200 micromol/L), or "non-phenylketonuria (PKU)-hyperphenylalaninemia" (<600 micromol/L). Recent studies revealed intellectual, neurologic, and neuropsychologic deficits as well as abnormalities of cerebral white matter (magnetic resonance imaging, MRI) in patients with early and adequately treated PKU. In addition deficits in IQ were reported for a group of 4-y-old patients with untreated mild PKU and non-PKU hyperphenylalaninemia (serum phenylalanine levels below 900 micromol/L). As a consequence, a lifelong diet with serum phenylalanine levels below 400 micromol/L was recommended even for those patients with serum phenylalanine levels remaining consistently between 400 and 600 micromol/L. Generally patients with non-PKU hyperphenylalaninemia were not treated, as a normal outcome was suspected, but the clinical development of patients with non-PKU hyperphenylalaninemia was not so far studied systematically. We assessed 28 untreated patients with non-PKU hyperphenylalaninemia (age: mean = 21.8, SD = 4.2 y) for IQ, school and job career, clinical-neurologic development, fine motor performances, selective and sustained attention, as well as for frontal lobe-dependent "executive functions." In addition, cranial MRI was obtained in 10 of these patients. Compared with healthy control subjects, matched for age, sex, and socioeconomic status, the patients reached normal results in all clinical and psychometric tests. Cranial MRI revealed no abnormalities. Additionally, no significant correlations between serum phenylalanine levels and test results were obtained. In the absence of any demonstrative effect, treatment is unlikely to be of significant effect in patients with non-PKU hyperphenylalaninemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284280     DOI: 10.1203/00006450-199709000-00020

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

Review 1.  Phenylketonuria: old disease, new approach to treatment.

Authors:  H L Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  Brain phenylalanine concentration in the management of adults with phenylketonuria.

Authors:  R A Moats; R Koch; K Moseley; P Guldberg; F Guttler; R G Boles; M D Nelson
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

3.  Modelling the phenylalanine blood level response during treatment of phenylketonuria.

Authors:  U Langenbeck; J Zschocke; U Wendel; V Hönig
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

4.  Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls.

Authors:  J Weglage; M Grenzebach; M Pietsch; R Feldmann; R Linnenbank; J Denecke; H G Koch
Journal:  J Inherit Metab Dis       Date:  2000-07       Impact factor: 4.982

5.  Cognitive function in untreated subjects with mild hyperphenylalaninemia: a systematic review.

Authors:  Noushin Rostampour; Rojin Chegini; Silva Hovsepian; Farzaneh Zamaneh; Mahin Hashemipour
Journal:  Neurol Sci       Date:  2022-06-21       Impact factor: 3.830

6.  Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

Authors:  J J Moyle; A M Fox; M Arthur; M Bynevelt; J R Burnett
Journal:  Neuropsychol Rev       Date:  2007-04-05       Impact factor: 7.444

7.  Cognitive functioning in mild hyperphenylalaninemia.

Authors:  Alicia de la Parra; María Ignacia García; Susan E Waisbren; Verónica Cornejo; Erna Raimann
Journal:  Mol Genet Metab Rep       Date:  2015-10-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.